Reliable detection of the Cystic Fibrosis causing mutations
Astra Biotech´s Cystic Fibrosis Microarray-on-a-chip is an easy to handle, quick and cost-efficient alternative to sequencing for the reliable detection of the most important Cystic Fibrosis causing mutations as a part of newborn screening. This was shown in a successful study at the University Mucoviscidosis Center "Christiane Herzog" of the University Hospital Carl Gustav Carus in Dresden which took place in autumn 2014. The tested version of the Cystic Fibrosis Microarray-on-a-chip kit allows the detection of 25 most important mutations in European population.
In the analysis of 66 patient´s samples the kit convinced with a clinical specificity of 99.8 % and a sensitivity of 100 %:
“Analysis of mutations with the Cystic Fibrosis microarray-on-a-chip is (…) a valid method easy to carry out (…).” 
“Practicability of analysis is easy and scanning (…) as well as evaluation by software is user-friendly and fast.” 
 Translated from the final study report “CFTR Mutationsdetektion mit dem Astra Biotech Testkit Cystic fibrosis microarray-on-a-chip“.